tetano
Editor, Senior Moderator
Pediatr Neurol
. 2024 Jan 1:152:87-92.
doi: 10.1016/j.pediatrneurol.2023.12.021. Online ahead of print. Accelerated Course of Cerebral Adrenoleukodystrophy After Coronavirus Disease 2019 Infection
Qiu-Hong Wang[SUP] 1 [/SUP], Jing Wang[SUP] 1 [/SUP], Yang-Yang Wang[SUP] 1 [/SUP], Wen He[SUP] 1 [/SUP], Chen Feng[SUP] 1 [/SUP], Jing Gao[SUP] 1 [/SUP], Qian Lu[SUP] 1 [/SUP], Yi Wang[SUP] 1 [/SUP], Shuo Dun[SUP] 1 [/SUP], Qi Zhang[SUP] 1 [/SUP], Li-Ping Zou[SUP] 2 [/SUP]
Affiliations
Background: Coronavirus disease 2019 (COVID-19) can not only infect the respiratory system but also affect the nervous system through the release of inflammatory factors. Our study aimed to investigate the effect of COVID-19 infection on cerebral adrenoleukodystrophy (ALD).
Methods: Changes in the neurological symptoms of cerebral ALD after infection with COVID-19 from January 2022 to February 2023 were retrospectively analyzed. The primary assessment indicator was the Neurologic Function Scale (NFS) score.
Results: A total of 17 male patients with cerebral ALD were enrolled, with a median age of 101 months (80 to 151 months). Among them, 11 (11 of 17, 64.7%) developed an exacerbation of neurological symptoms after COVID-19 infection. Two patients with NFS = 0 started presenting with neurological symptoms after infection. Fifteen patients were in the advanced stage (NFS >1 and/or Loes score >9), of which nine did not progress to major functional disabilities (MFDs). Seven of the nine patients (77.8%) experienced an increase in NFS scores, ranging from 1 to 9 points, within two weeks of COVID-19 infection, with four of them experiencing MFDs. For the other six patients who had progressed to MFDs, there was not much room for further degeneration, so the NFS score did not increase after COVID-19 infection. No deaths related to COVID-19 infection occurred.
Conclusions: COVID-19 infection may aggravate neurological symptoms of cerebral ALD, particularly among patients who have not yet progressed to MFDs. Therefore, COVID-19 may accelerate the course of cerebral ALD, so protecting patients from infection is essential for maintaining the stability of the disease.
Keywords: Accelerate; Adrenoleukodystrophy; COVID-19; Infection; Neurological.
. 2024 Jan 1:152:87-92.
doi: 10.1016/j.pediatrneurol.2023.12.021. Online ahead of print. Accelerated Course of Cerebral Adrenoleukodystrophy After Coronavirus Disease 2019 Infection
Qiu-Hong Wang[SUP] 1 [/SUP], Jing Wang[SUP] 1 [/SUP], Yang-Yang Wang[SUP] 1 [/SUP], Wen He[SUP] 1 [/SUP], Chen Feng[SUP] 1 [/SUP], Jing Gao[SUP] 1 [/SUP], Qian Lu[SUP] 1 [/SUP], Yi Wang[SUP] 1 [/SUP], Shuo Dun[SUP] 1 [/SUP], Qi Zhang[SUP] 1 [/SUP], Li-Ping Zou[SUP] 2 [/SUP]
Affiliations
- PMID: 38237318
- DOI: 10.1016/j.pediatrneurol.2023.12.021
Background: Coronavirus disease 2019 (COVID-19) can not only infect the respiratory system but also affect the nervous system through the release of inflammatory factors. Our study aimed to investigate the effect of COVID-19 infection on cerebral adrenoleukodystrophy (ALD).
Methods: Changes in the neurological symptoms of cerebral ALD after infection with COVID-19 from January 2022 to February 2023 were retrospectively analyzed. The primary assessment indicator was the Neurologic Function Scale (NFS) score.
Results: A total of 17 male patients with cerebral ALD were enrolled, with a median age of 101 months (80 to 151 months). Among them, 11 (11 of 17, 64.7%) developed an exacerbation of neurological symptoms after COVID-19 infection. Two patients with NFS = 0 started presenting with neurological symptoms after infection. Fifteen patients were in the advanced stage (NFS >1 and/or Loes score >9), of which nine did not progress to major functional disabilities (MFDs). Seven of the nine patients (77.8%) experienced an increase in NFS scores, ranging from 1 to 9 points, within two weeks of COVID-19 infection, with four of them experiencing MFDs. For the other six patients who had progressed to MFDs, there was not much room for further degeneration, so the NFS score did not increase after COVID-19 infection. No deaths related to COVID-19 infection occurred.
Conclusions: COVID-19 infection may aggravate neurological symptoms of cerebral ALD, particularly among patients who have not yet progressed to MFDs. Therefore, COVID-19 may accelerate the course of cerebral ALD, so protecting patients from infection is essential for maintaining the stability of the disease.
Keywords: Accelerate; Adrenoleukodystrophy; COVID-19; Infection; Neurological.
